Smart Technology, Healthy Life

智慧科技,健康生活。

关于慧康集团

About Huikang

      西安慧康企业运营管理集团有限公司(简称:慧康集团)成立于2012年。慧康集团以生物科技、美容连锁为核心业务集群,构建全产业链式的国际化企业运营体系,塑造生物科技应用于社会生活的核心价值。
       慧康集团将商业实践与社会价值相融合,追求新产业时代下的可持续发展,斥资5亿元建设的生物科技产业园区,占地40亩,总建筑面积6.5万平方米,将科研、管理、培训、生产集于一体。截至2024年6月,慧康集团旗下子公司共有162项专利,包括国家发明专利84项、外观专利18项、实用新型专利29项,中国香港专利17项、国际专利14项;现有国家I类新药1项,医疗器械2项,西安市博士后创新基地项目3项,重点科研项目13项。
       陕西慧康生物科技有限责任公司发起的“慧康•中国肽库”项目(简称“中国肽库”),将建立蛋白与多肽原料研发与供应基地,抢占“蓝海战略”引领下的价值创新高地。

企业文化

HuiKang Culture

  • 共同愿景

    生物科技进化人类生活。

  • 企业价值观

    共创、共赢、共享。

  • 使命宗旨

    为员工谋福利,为企业创价值,为社会做贡献。

  • 事业信条

    知行合一,敬天爱人。

  • 用人原则

    以人为本、以德为先、机会均等、任贤使能。


高层领导

HuiKang Leadership

相伟 Xiang Wei

董事长 Chairman of the Board

中国资深媒体人,先后担任《重庆时报》《文化报》《华商报》等多家传媒高管及负责人,在任陕西华商报社党委书记、执行社长期间,通过创新产业运营模式,推进多元化经营与全媒体融合,率领华商报业创下历史最好业绩。
资本运营策略师,曾兼任多家上市公司战略决策顾问,首创“相氏系统管理环”公司战略与风险管理系统,长期致力于生物科技时代下新经济法则研究,人类进入生物文明时代倡言者。

Senior media editor in China. He has successively served as the senior executive and principal of many media companies, such as Chongqing Times, Cultural Daily and Huashang Daily. During his tenure as Party Secretary and executive president of Shaanxi Huashang Daily, he led Huashang Newspaper to achieve the best performance in history by innovating the industrial operation mode and promoting the integration of diversified operation & omnimedia convergence.
Capital Operations strategist. He doubled in many listed companies as a strategic counselor, initiated Corporate Strategy and Risk Management System, named "Xiang's System Management Loop", constantly strived to study the new economic laws in the era of biotechnology. He is an advocate of mankind entering the age of biological civilization.

孙剑 Sun Jian

董事 Board Member

发展生物科技,为社会做贡献,是孙剑先生信奉的宗旨。
近20年的经营中,他对大健康产业、生物科技具有非常执着的信念、前瞻的战略眼光、卓越的运营能力,以及丰富的管理经验。
2010年,他基于蛋白与多肽的应用研究,投资发展生物科技大健康业务。目前,已建设并投入使用65000平米慧康生物产业园,配备国际先进的科研以及生产设备、经营范围涵盖新药、基因治疗、医疗器械以及化妆品的研发、生产与销售。

Developing biotechnology and making contributions to society are Mr. Sun’s beliefs.
From nearly 20 years of operation, he got a firm conviction in the massive health industry and biotechnology, along with forward-looking strategic vision, excellent operational capabilities and rich management experience.
In 2010, he invested in the massive health industry based on applied research in proteins and peptides. At present, a 65,000 m2 HuiKang Biological Industrial Park has been built and put into operation with international advanced scientific research and production equipment. The business scope covers the R&D of new drugs, gene therapy, medical devices and the R&D, manufacture and sales of cosmetics.


大事记

Memorabilia


  • 2021 

    慧康生物荣登全球百强创新榜新材料组唯一中国企业。

    Huikang Bio-Tech was the only Chinese enterprise in the new material group of the Global Top 100 Innovative list.

  • 2021 

    慧康生物获教育部金属材料强度国家重点实验室资助。

    Huikang Bio-Tech was subsidize by the State Key Laboratory of Mechanical Behavior of Materials, Ministry of Education.

  • 2021 

    慧康生物新冠病毒阻断肽项目获博士后创新基地一等资助项目。

    HuiKang Novel Coronavirus blocking peptide project obtained class I fund of Postdoctoral Innovation Base.

  • 2020 

    六胜肽精华液获陕西省重点新产品。

    Argireline Serum received the honor of Shaanxi Key New Products.

  • 2020 

    胶原蛋白科研成果刊登于著名学术期刊《International Journal of Biological Macromolecules》。

    The scientific achievements of collagen have been published in famous academic journal International Journal of Biological Macromolecules.

  • 2020 

    ACTII昂刻品牌诞生。

    The brand ACTII was born.

  • 2019 

    慧康生物科技产业园正式投入生产。

    HuiKang Biotechnology Industrial Park officially put into operation.

  • 2018 

    成功承办2018全球硬科技大会暨一带一路创新合作大会的分论坛——国际蛋白质与多肽大会。

    Successfully hosted the International Protein and Peptides Conference, a sub forum of the 2018 Global Hard and Core Conference and the Belt and Road Innovation conference.

  • 2018 

    英国《自然》杂志子刊报道“慧康•中国肽库”。

    Introduction article of HuiKang • China Peptide Bank published in the sub Journal of Nature.

  •  2017

    启动“慧康•中国肽库(中国肽库)”一期建设计划。

    Launched the Phase I Construction Plan of HuiKang• China Peptide Bank.

  •  2017

    启动生物高科化妆品ODM业务。

    Started Bio-tech cosmetics business.

  •  2017

    生物高科护肤品牌汝新美肌诞生。

    The bio-tech cosmetics brand Ye New Skin was debuted.

  •  2016

    启动2项国家Ⅰ类新药的研发。

    Initiate the R&D of two national class I new drugs.

  •  2012

    西安慧康企业运营管理集团有限公司成立。

    Xi 'an HuiKang Enterprise Operation Management Group Co., LTD was founded.

  •  2012

    获得首个中国发明专利。

    Obtained the first national invention patent.

  •  2011

    鱼化寨慧康生物科技园破土动工。

    HuiKang Biotechnology Industrial Park broke groud and started building.

  •  2011

    以蛋白多肽为核心成分的系列护肤产品相继面世。

    A series of skin care products with protein and peptides as the core ingredients have came out after one and another..

  •  2011

    成功研发出基因重组人胶原蛋白。

    Recombinant human collagen was successfully developed..

  •  2010

    慧康生物研发中心正式成立。

    HuiKang R&D Center was set up.

  •  2001

    陕西东大生化科技有限责任公司(慧康生物前身)成立。

    Shaanxi Dongda Biochemical Technology Co., LTD. (the predecessor of HuiKang Bio-Tech) was established.


核心实力

Core Innovation


截至2022年10月底,慧康集团旗下子公司共有134项专利,包括国家发明专利65项、外观专利17项、实用新型专利25项,中国香港专利12项、 国际专利15项。


中国国内专利



中国香港专利



国际专利



伊蔓蒂外观设计和实用新型专利


慧康生物科技园

HuiKang bio-tech industrial park

投资5.2亿元,占地42亩,建筑面积6.5万平方米。
合成多肽中试放大系统
蛋白多肽制剂中试放大生产系统
重组蛋白中试放大生产系统

慧康•中国肽库 (中国肽库)

China Peptide bank

“中国肽库”项目计划构建一个序列精准的商业肽库,或称平行肽库,共计超过175000条肽,未来将成为人类共享的宝库。


荣誉与交流

Honor and Cooperation



重点项目

Key Projects


国家高新技术企业

National High-tech Enterprise

 

2项国家I类新药

Two National Class I New Drug

 

蛋白多肽类功能因子产业化生产——国家“十二五”科技支撑计划

Industrialized Production of Protein Peptides Functional Factors- National Science and Technology Support Plan during the 12th Five-Year Plan Period

 

基因重组人胶原蛋白规模化生产项目——西安市企业技术创新工程项目

Pilot scale production of recombinant human EGF- Xi 'an Enterprise Science and Technology Little Giant Plan

 

基因重组人胶原蛋白美容液——陕西省新产品项目

Large-scale Production Project of Recombinant Human Collagen - Xi 'an Enterprise Technology Innovation Project

 

基因重组人表皮生长因子中试放大生产项目——西安市企业科技小巨人计划

Pilot scale production of recombinant human EGF- Xi 'an Enterprise Science and Technology Little Giant Plan

 

SOD、溶菌酶——西安市技术创新项目计划

SOD/LYZ- Xi 'an Technology Innovation Project Plan

 


社会公益

Social Benefit 


扶贫助学

poverty relief and

 

公益援建

Public Construction Aid

 

救灾捐助

Disaster Relief Donations

 

Copyright © 2017 慧康集团保留所有权利/

陕ICP备17008662号-1

友情链接:

慧康生物研发中心